Paul Hastings advised Kyverna Therapeutics in connection with the company’s upsized initial public offering. Kyverna Therapeutics, Inc., a patient-centered clinical-stage biopharmaceutical company focused on developing cell...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here